Trial Profile
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally Suppressed Subjects With Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs GS 4774 (Primary)
- Indications Hepatitis B
- Focus Proof of concept; Therapeutic Use
- Sponsors Gilead Sciences
- 19 May 2016 Results published in the Journal of Hepatology
- 13 Nov 2015 Results from this trial will be presented at the Liver Meeting 2015, according to a GlobeImmune media release.
- 27 May 2015 Primary endpoint (Mean change in log10 IU/mL serum hepatitis B surface antigen (HBsAg) from Baseline to Week 24) has not been met, according to a GlobeImmune media release